Breast Cancer Clinical Trial
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
The purpose of this study is to determine if it is feasible, safe, and effective to use Cyberknife radiotherapy to deliver partial breast radiotherapy after lumpectomy.Patients meeting eligibility criteria will be invited to participate. Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions. Short-term and long-term toxicity will be assessed as well as Tumor control and site of failure (if any).
This study will determine the feasibility and toxicity of a short course of accelerated radiotherapy as adjuvant treatment for early stage breast cancer. Successful completion of this project may provide a rationale to offer this treatment for select patients with the benefit of potentially less tissue damage and a shorter overall course of therapy. These improvements may ultimately allow more patients the opportunity of breast conserving therapy to treat their cancer
Diagnosis of breast malignancy, stage T1
Surgical treatment with lumpectomy
age 60 or older
resection margins negative by at least 2mm
pathologic free of nodal metastases (N0, i- or i+)
Post-lumpectomy cavity to whole breast ratio must be less than or equal to 30%
Prior radiotherapy to the breast
Pure DCIS histology
Presence of extensive intraductal component
Node positive disease (N1 or greater)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Duluth Minnesota, 55805, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.